|Bid||41.15 x 600|
|Ask||41.20 x 2300|
|Day's Range||41.13 - 41.24|
|52 Week Range||35.15 - 44.44|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
The U.S. equity market experienced a 10% drawdown in February, breaking into an official correction. If history has anything to say about it, the stock market and related exchange traded funds may enjoy ...
Analysts estimate Merck's gross profit margin to come in at 75.8% for 3Q17, a 0.5% increase as compared to its gross profit margin in 3Q16.
Johnson & Johnson’s (JNJ) consumer segment reported revenue of $3.5 billion in 2Q17, a growth of 1.7% from the revenue of $3.4 billion reported in 2Q16. This figure includes 2.3%…
Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.
We discussed the products that contribute to the growth of Pfizer’s (PFE) revenues in 2Q17. Let's now take a look at the products that have impacted revenue growth in 2Q17.
As of July 31, 2017, of the 22 analysts tracking Pfizer, ten recommend a “buy” for the stock, while 11 recommend a “hold,” and one recommends a “sell."
Analysts expect Bristol-Myers Squibb’s (BMY) top line to rise 4.4% to ~$5.1 billion in 2Q17. They expect its earnings per share to be $0.74 in the quarter.
Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.
Johnson & Johnson’s (JNJ) medical devices segment grew ~4.9% to ~$6.7 billion for 2Q17, compared with $6.4 billion in 2Q16. This rise included an operational increase of 5.9%, and was offset…
Johnson & Johnson continued its long streak of earnings beat and offered an upbeat outlook for the full year. However, it lagged our revenue estimate.
Johnson & Johnson’s (JNJ) Medical Devices segment deals with the vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care franchises.
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer’s portfolio, which comprises the Innovative Health and Essential Health segments, includes various medicines, vaccines, and ...
With operational growth across all segments, Johnson & Johnson reported operational growth of 2.0% in revenues to ~$17.8 billion for 1Q17.
Tanezumab is an investigational drug co-developed by Pfizer (PFE) and Eli Lilly (LLY) for pain management in chronic pain related to cancer, lower back pain, and osteoarthritis.
Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.
Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of ...